Ticagrelor resistance: a case series and algorithm for management of non-responders
- 2 July 2021
- journal article
- review article
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 14 (2) , 179-183
Abstract
The placement of cervical and intracranial stents requires the administration of antiplatelet drugs to prevent thromboembolic complications. Ticagrelor has emerged as the most widely used alternative in clopidogrel non-responders owing to its potent antiplatelet effects. Because ticagrelor does not require hepatic activation, many neurointerventionalists choose to forgo laboratory testing of platelet inhibition. In rare instances, patients may not achieve adequate platelet inhibition following ticagrelor administration. In this paper we review the mechanism of action of ticagrelor and its use in cerebrovascular procedures. We present two cases of ticagrelor non-responsiveness from two high-volume cerebrovascular centers, discuss their management, and propose an algorithm for managing ticagrelor non-responsiveness.Keywords
This publication has 110 references indexed in Scilit:
- Evaluation of Crushed Ticagrelor Tablet Doses: Recovery Following Crushing and Naso-gastric Tube Passage Ex VivoDrugs in R&D, 2013
- Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 2012
- Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional proceduresJournal of NeuroInterventional Surgery, 2012
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Clopidogrel pathwayPharmacogenetics and Genomics, 2010
- Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteersBritish Journal of Clinical Pharmacology, 2010
- Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009